Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2017

Aug 14, 2017

SELL
N/A
-433,978 Closed
0 $0
Q1 2017

May 15, 2017

SELL
N/A
-296,474 Reduced 40.59%
433,978 $58 Million
Q4 2016

Feb 14, 2017

BUY
N/A
226,807 Added 45.03%
730,452 $73.2 Million
Q3 2016

Nov 14, 2016

BUY
N/A
503,645
503,645 $47.5 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.1B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Viking Global Investors LP Portfolio

Follow Viking Global Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Viking Global Investors LP with notifications on news.